Evaluation of 1,2,3-Triazoles As Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809

Overview

Journal Chemistry

Specialty Chemistry

Date 2019 Jan 17

PMID 30650214

Citations 9

Authors

Jake E Doiron

Christina A Le

Britton K Ody

Jonathon B Brace

Savannah J Post

Nathan L Thacker

Harrison M Hill

Gary W Breton

Matthew J Mulder

Sichen Chang

Thomas M Bridges

Liping Tang

Wei Wang

Steven M Rowe

Stephen G Aller

Mark Turlington

Affiliations

Soon will be listed here.

Abstract

The 1,2,3-triazole has been successfully utilized as an amide bioisostere in multiple therapeutic contexts. Based on this precedent, triazole analogues derived from VX-809 and VX-770, prominent amide-containing modulators of the cystic fibrosis transmembrane conductance regulator (CFTR), were synthesized and evaluated for CFTR modulation. Triazole 11, derived from VX-809, displayed markedly reduced efficacy in F508del-CFTR correction in cellular TECC assays in comparison to VX-809. Surprisingly, triazole analogues derived from potentiator VX-770 displayed no potentiation of F508del, G551D, or WT-CFTR in cellular Ussing chamber assays. However, patch clamp analysis revealed that triazole 60 potentiates WT-CFTR similarly to VX-770. The efficacy of 60 in the cell-free patch clamp experiment suggests that the loss of activity in the cellular assay could be due to the inability of VX-770 triazole derivatives to reach the CFTR binding site. Moreover, in addition to the negative impact on biological activity, triazoles in both structural classes displayed decreased metabolic stability in human microsomes relative to the analogous amides. In contrast to the many studies that demonstrate the advantages of using the 1,2,3-triazole, these findings highlight the negative impacts that can arise from replacement of the amide with the triazole and suggest that caution is warranted when considering use of the 1,2,3-triazole as an amide bioisostere.

Citing Articles

Probing Isosteric Replacement for Immunoadjuvant Design: Bis-Aryl Triazole Trehalolipids are Mincle Agonists.

Foster M, Dangerfield E, Timmer M, Stocker B, Wilkinson B ACS Med Chem Lett. 2024; 15(6):899-905.

PMID: 38894898 PMC: 11181483. DOI: 10.1021/acsmedchemlett.4c00100.

Overview of CFTR activators and their recent studies for dry eye disease: a review.

Wu J, Wang X, Zhao Y, Hou Y, Gong P RSC Med Chem. 2023; 14(12):2459-2472.

PMID: 38107177 PMC: 10718525. DOI: 10.1039/d3md00448a.

Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.

Lester A, Sandman M, Herring C, Girard C, Dixon B, Ramsdell H Biochemistry. 2023; 62(16):2503-2515.

PMID: 37437308 PMC: 10433520. DOI: 10.1021/acs.biochem.3c00165.

Additive Potentiation of R334W-CFTR Function by Novel Small Molecules.

Bacalhau M, Ferreira F, Silva I, Buarque C, Amaral M, Lopes-Pacheco M J Pers Med. 2023; 13(1).

PMID: 36675763 PMC: 9862739. DOI: 10.3390/jpm13010102.

Click Chemistry of Selenium Dihalides: Novel Bicyclic Organoselenium Compounds Based on Selenenylation/Bis-Functionalization Reactions and Evaluation of Glutathione Peroxidase-like Activity.

Musalov M, Potapov V Int J Mol Sci. 2022; 23(24).

PMID: 36555274 PMC: 9779772. DOI: 10.3390/ijms232415629.

References

Serohijos A, Hegedus T, Aleksandrov A, He L, Cui L, Dokholyan N . Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A. 2008; 105(9):3256-61. PMC: 2265173. DOI: 10.1073/pnas.0800254105. View

Goncz K, Kunzelmann K, Xu Z, Gruenert D . Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. Hum Mol Genet. 1998; 7(12):1913-9. DOI: 10.1093/hmg/7.12.1913. View

Ballard T, Richards J, Wolfe A, Melander C . Synthesis and antibiofilm activity of a second-generation reverse-amide oroidin library: a structure-activity relationship study. Chemistry. 2008; 14(34):10745-61. DOI: 10.1002/chem.200801419. View

Sloane P, Rowe S . Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med. 2010; 16(6):591-7. PMC: 3733473. DOI: 10.1097/MCP.0b013e32833f1d00. View

Mugnaini C, Nocerino S, Pedani V, Pasquini S, Tafi A, De Chiaro M . Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. ChemMedChem. 2012; 7(5):920-34. PMC: 3516921. DOI: 10.1002/cmdc.201100573. View

Wang W, Li G, Clancy J, Kirk K . Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs. J Biol Chem. 2005; 280(25):23622-30. DOI: 10.1074/jbc.M503118200. View

Christodoulou M, Mori M, Pantano R, Alfonsi R, Infante P, Botta M . Click Reaction as a Tool to Combine Pharmacophores: The Case of Vismodegib. Chempluschem. 2020; 80(6):938-943. DOI: 10.1002/cplu.201402435. View

Keck T, Banala A, Slack R, Burzynski C, Bonifazi A, Okunola-Bakare O . Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands. Bioorg Med Chem. 2015; 23(14):4000-12. PMC: 4468002. DOI: 10.1016/j.bmc.2015.01.017. View

Mamidyala S, Finn M . In situ click chemistry: probing the binding landscapes of biological molecules. Chem Soc Rev. 2010; 39(4):1252-61. DOI: 10.1039/b901969n. View

10.

Jih K, Hwang T . Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci U S A. 2013; 110(11):4404-9. PMC: 3600496. DOI: 10.1073/pnas.1215982110. View

11.

Mohammed I, Kummetha I, Singh G, Sharova N, Lichinchi G, Dang J . 1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists. J Med Chem. 2016; 59(16):7677-82. PMC: 5534211. DOI: 10.1021/acs.jmedchem.6b00247. View

12.

Gottschalk L, Vecchio-Pagan B, Sharma N, Han S, Franca A, Wohler E . Creation and characterization of an airway epithelial cell line for stable expression of CFTR variants. J Cyst Fibros. 2015; 15(3):285-94. PMC: 4879073. DOI: 10.1016/j.jcf.2015.11.010. View

13.

Hwang T, Yeh J, Zhang J, Yu Y, Yeh H, DeStefano S . Structural mechanisms of CFTR function and dysfunction. J Gen Physiol. 2018; 150(4):539-570. PMC: 5881446. DOI: 10.1085/jgp.201711946. View

14.

Seth Horne W, Yadav M, Stout C, Ghadiri M . Heterocyclic peptide backbone modifications in an alpha-helical coiled coil. J Am Chem Soc. 2004; 126(47):15366-7. PMC: 1868409. DOI: 10.1021/ja0450408. View

15.

Audisio D, Messaoudi S, Peyrat J, Brion J, Alami M . A general copper powder-catalyzed Ullmann-type reaction of 3-halo-4(1H)-quinolones with various nitrogen-containing nucleophiles. J Org Chem. 2011; 76(12):4995-5005. DOI: 10.1021/jo200680j. View

16.

Bobadilla J, Macek Jr M, Fine J, Farrell P . Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat. 2002; 19(6):575-606. DOI: 10.1002/humu.10041. View

17.

Phuan P, Veit G, Tan J, Roldan A, Finkbeiner W, Lukacs G . Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014; 86(1):42-51. PMC: 4054004. DOI: 10.1124/mol.114.092478. View

18.

Eckford P, Ramjeesingh M, Molinski S, Pasyk S, Dekkers J, Li C . VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol. 2014; 21(5):666-78. DOI: 10.1016/j.chembiol.2014.02.021. View

19.

Bonandi E, Christodoulou M, Fumagalli G, Perdicchia D, Rastelli G, Passarella D . The 1,2,3-triazole ring as a bioisostere in medicinal chemistry. Drug Discov Today. 2017; 22(10):1572-1581. DOI: 10.1016/j.drudis.2017.05.014. View

20.

Yu H, Burton B, Huang C, Worley J, Cao D, Johnson Jr J . Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012; 11(3):237-45. DOI: 10.1016/j.jcf.2011.12.005. View